Nous-209 Genetic Vaccine for the Treatment of MSI-H Colorectal, Gastric and Gastro-esophageal junction Tumors
Clinicaltrials.gov identifier:
NCT04041310
Treatment
Treatment study for people with advanced colorectal, gastric and gastro-esophageal junction tumors
Study Contact Information:
Questions about the study can be directed to the study contacts listed below or to Dr. Patricia Delaite at [email protected]
Nous-209 Genetic Vaccine for the Treatment of Microsatellite -High (MSI-H) Colorectal, Gastric and Gastro-esophageal junction Tumors
About the Study
The goal of this cancer treatment study is to find the best dose and learn how safe and effective this cancer vaccine is for treating advanced colorectal, gastric and gastro-esophageal junction tumors that test positive for the biomarkers or . Participants will receive the vaccine in combination with the drug Keytruda (pembrolizumab). NOTE: This study is no longer enrolling people.